scispace - formally typeset
Open AccessJournal ArticleDOI

Beta-Amyloid Peptides Enhance the Proliferative Response of Activated CD4+CD28+ Lymphocytes from Alzheimer Disease Patients and from Healthy Elderly

Reads0
Chats0
TLDR
It is suggested that the effect of Aβ peptides on the immune system of AD patients does not depend on the specific reactivity to Aβ epitope(s), but is rather a consequence of an unspecific modulation of the cell cycle dynamics and cytokine production by T cells, occurring simultaneously in a huge proportion of A β peptide-exposed T lymphocytes and affecting theimmune system performance.
Abstract
Alzheimer's disease (AD) is the most frequent form of dementia among elderly. Despite the vast amount of literature on non-specific immune mechanisms in AD there is still little information about the potential antigen-specific immune response in this pathology. It is known that early stages of AD include β-amyloid (Aβ)- reactive antibodies production and inflammatory response. Despite some evidence gathered proving cellular immune response background in AD pathology, the specific reactions of CD4+ and CD8+ cells remain unknown as the previous investigations yielded conflicting results. Here we investigated the CD4+CD28+ population of human peripheral blood T cells and showed that soluble β-amyloids alone were unable to stimulate these cells to proliferate significantly, resulting only in minor, probably antigen-specific, proliferative response. On the other hand, the exposure of in vitro pre-stimulated lymphocytes to soluble Aβ peptides significantly enhanced the proliferative response of these cells which had also lead to increased levels of TNF, IL-10 and IL-6. We also proved that Aβ peptide-enhanced proliferative response of CD4+CD28+ cells is autonomous and independent from disease status while being associated with the initial, ex vivo activation status of the CD4+ cells. In conclusion, we suggest that the effect of Aβ peptides on the immune system of AD patients does not depend on the specific reactivity to Aβ epitope(s), but is rather a consequence of an unspecific modulation of the cell cycle dynamics and cytokine production by T cells, occurring simultaneously in a huge proportion of Aβ peptide-exposed T lymphocytes and affecting the immune system performance.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease

TL;DR: In this article, the authors identify a particular immune profile in the peripheral blood (PB) and cerebrospinal fluid (CSF) in patients with mild Alzheimer's disease (mAD) and mild cognitive impairment (MCI) and its potential functional relevance and association with neurodegeneration.
Journal ArticleDOI

Role of the peripheral innate immune system in the development of Alzheimer's disease.

TL;DR: The activation status of peripheral innate immune cells may represent an early biomarker of the upcoming impact on the brain of Alzheimer's disease, and the modulation of these cells may become a useful mechanism for modifying disease progression.
Journal ArticleDOI

Immunosenescence, inflammation and Alzheimer’s disease

TL;DR: Data is reviewed focusing on changes of some immunoinflammatory parameters observed in patients affected by Alzheimer’s disease to help explain the inflammation commonly present in many age-associated diseases.
Journal ArticleDOI

Aging enhances release of exosomal cytokine mRNAs by Aβ1-42-stimulated macrophages

TL;DR: An Aβ level relevant to neurodegeneration elicited broad M cytokine and ex‐mRNA responses that were significantly greater in the old subjects, but only narrow and age‐independent CD4‐Tm responses.
References
More filters
Journal ArticleDOI

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

TL;DR: It is reported that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis, and treatment of the older animals markedly reduced the extent and progression of these AD-like neuropathologies.
Journal ArticleDOI

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

TL;DR: It is shown that vaccination with Aβ protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease and may prevent and, possibly, treat Alzheimer's dementia.
Journal ArticleDOI

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

TL;DR: Aβ immunization reduces both deposition of cerebral fibrillar Aβ and cognitive dysfunction in the TgCRND8 murine model of Alzheimer's disease without, however, altering total levels of Aβ in the brain, which implies that either a ∼50% reduction in dense-cored Aβ plaques is sufficient to affect cognition, or that vaccination may modulate the activity/abundance of a small subpopulation of especially toxic Aβ species.
Related Papers (5)